|
[1]
|
Chukwueke, U.N. and Nayak, L. (2019) Central Nervous System Lymphoma. Hematology/Oncology Clinics of North America, 33, 597-611. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Ferreri, A.J.M. (2017) Therapy of Primary CNS Lymphoma: Role of Intensity, Radiation, and Novel Agents. Hematology: The American Society of Hematology Education Program, 2017, 565-577. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Ferreri, A.J.M., Reni, M., Foppoli, M., et al. (2009) High-Dose Cytarabine plus High-Dose Methotrexate versus High-Dose Methotrexate Alone in Patients with Primary CNS Lymphoma: A Randomised Phase 2 Trial. Lancet, 374, 1512-1520. [Google Scholar] [CrossRef]
|
|
[4]
|
Langner-Lemercier, S., Houillier, C., Soussain, C., et al. (2016) Primary CNS Lymphoma at First Relapse/Progression: Characteristics, Management, and Outcome of 256 Pa-tients from the French LOC Network. Neuro-Oncology, 18, 1297-1303. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Preusser, M., Woehrer, A., Koperek, O., Rottenfusser, A., Dieckmann, K., Gatterbauer, B., et al. (2010) Primary Central Nervous System Lymphoma: A Clinicopathological Study of 75 Cases. Pathology, 42, 547-552. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Grommes, C, Pastore, A, Palaskas, N, Tang, S.S., Campos, C., Schartz, D., et al. (2017) Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery, 7, 1018-1029. [Google Scholar] [CrossRef]
|
|
[7]
|
Vetrie, D., Vorechovsky, I., Sideras, P., Holland, J., Davies, A., Flinter, F., Hammarström, L., Kinnon, C., Levinsky, R., Bobrow, M., et al. (1993) The Gene Involved in X-Linked Agammaglobulinaemia Is a Member of the src Family of Protein-Tyrosine Kinases. Nature, 361, 226-233. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Buggy, J.J. and Elias, L. (2012) Bruton Tyrosine Kinase (BTK) and Its Role in B-Cell Malignancy. International Reviews of Immunology, 31, 119-132. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., Grant, B., Sharman, J.P., Coleman, M., Wierda, W.G., et al. (2013) Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 369, 32-42. [Google Scholar] [CrossRef]
|
|
[10]
|
Hendriks, R.W., de Bruijn, M.F., Maas, A., Dingjan, G.M., Karis, A. and Grosveld, F. (1996) Inactivation of Btk by Insertion of lacZ Reveals Defects in B Cell Development Only Past the Pre-B Cell Stage. The EMBO Journal, 15, 4862-4872. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Kil, L.P., de Bruijn, M.J., van Nimwegen, M., Corneth, O.B.J., Piet van Hamburg, J., Dingjan, G.M., Thaiss, F., Rimmelzwaan, G.F., Elewaut, D., Delsing, D., et al. (2012) Btk Levels Set the Threshold for B-Cell Activation and Negative Selection of Autoreactive B Cells in Mice. Blood, 119, 3744-3756. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Liang, C., Tian, D., Ren, X., Ding, S., Jia, M., Xin, M. and Thareja, S. (2018) The Development of Bruton’s Tyrosine Kinase (BTK) Inhibitors from 2012-2017: A Mini-Review. European Journal of Medicinal Chemistry, 151, 315-326. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Dingjan, G.M., Middendorp, S., Dahlenborg, K., Maas, A., Grosveld, F. and Hendriks, R.W. (2001) Bruton’s Tyrosine Kinase Regulates the Activation of Gene Rearrangements at the Lambda Light Chain Locus in Precursor B Cells in the Mouse. Journal of Experimental Medicine, 193, 1169-1178. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Ysebaerta, L. and Michallet, A.-S. (2014) Bruton’s Tyrosine Kinase Inhibitors: Lessons Learned from Bench-to-Bedside (first) Studies. Current Opinion in Oncology, 26, 463-468. [Google Scholar] [CrossRef]
|
|
[15]
|
Carnero Contentti, E. and Correale, J. (2020) Bruton’s Ty-rosine Kinase Inhibitors: A Promising Emerging Treatment Option for Multiple Sclerosis. Expert Opinion on Emerging Drugs, 25, 377-381. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Wang, B., Deng, Y., Chen, Y., Yu, K., Wang, A., Liang, Q., Wang, W., Chen, C., Wu, H., Hu, C., et al. (2017) Structure-Activity Relationship Investigation for Benzonaphthyridi-none Derivatives as Novel Potent Bruton’s Tyrosine Kinase (BTK) Irreversible Inhibitors. European Journal of Medici-nal Chemistry, 137, 545-557. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Yoon, Y. (2014) Small Chemicals with Inhibitory Effects on PtdIns(3,4,5)P3 Bindingof Btk PH Domain. Bioorganic & Medicinal Chemistry Letters, 24, 2334-2339. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Jiang, Z., Liang, Z., Shen, B. and Hu, G. (2015) Computational Analysis of the Binding Specificities of PH Domains. BioMed Research International, 2015, Article ID: 792904. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Pan, Z., Scheerens, H., Li, S.J., Schultz, B.E., Sprengeler, P.A., Burrill, L.C., Mendonca, R.V., Sweeney, M.D., Scott, K.C., Grothaus, P.G., et al. (2007) Discovery of Selective Irreversible In-hibitors for Bruton’s Tyrosine Kinase. ChemMedChem, 2, 58-61. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Simar, P.S., Floris, D. and Rudi, W.H. (2018) Role of Bruton’s Tyrosine Kinase in B Cells and Malignancies. Molecular Cancer, 17, Article No. 57. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Zuo, Y.Y. and Pan, Z.Y. (2017) Small-Molecule Inhibitors of Bruton’s Tyrosine Kinase. In: Waring, M.J., Ed., Cancer II. Topics in Medicinal Chemistry, Vol. 28, Springer, Cham, 75-104. [Google Scholar] [CrossRef]
|
|
[22]
|
Burger, J.A. and Wiestner, A. (2018) Targeting B Cell Receptor Signalling in Cancer: Preclinical and Clinical Advances. Nature Reviews Cancer, 18,148-167. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Brullo, C., Villa, C., Tasso, B., Russo, E. and Spallarossa, A. (2021) Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. International Journal of Molecular Sciences, 22, Ar-ticle No. 7641. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Wang, X.H., Wong, J., Sevinsky, C.J., Kokabee, L., Khan, F., Sun, Y. and Conklin, D.S. (2016) Bruton’s Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. Mo-lecular Cancer Therapeutics, 15, 2198-2208. [Google Scholar] [CrossRef]
|
|
[25]
|
Roskoski Jr., R. (2020) Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors: A 2020 Update. Pharmacological Research, 152, Article ID: 104609. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Harris, C.M., Foley, S.E., Goedken, E.R., Michalak, M., Murdock, S. and Wilson, N.S. (2018) Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase. SLAS Discovery, 23, 1040-1050. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Johnson, A.R., Kohli, P.B., Katewa, A., Gogol, E., Belmont, L.D., Choy, R., Penuel, E., Burton, L., Eigenbrot, C., Yu, C., et al. (2016) Battling Btk Mutants with Non Covalent Inhibitors That Overcome Cys481 and Thyr474 Mutation. ACS Chemical Biology, 11, 2897-2907. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Liu, L.Y., Shi, B.Y., Wan, X.Q. and Xiang, H. (2018) Strategies to Overcome Resistance Mutations of Bruton’s Tyrosine Kinase Inhibitor Ibrutinib. Future Medicinal Chemistry, 10, 343-356. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Maddocks, K.J., Ruppert, A.S., Lozanski, G., Heerema, N.A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L.L., et al. (2015) Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients with Chronic Lymphocytic Leukemia. JAMA Oncology, 1, 80-87. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Woyach, J.A., Furman, R.R., Liu, T.M., Ozer, H.G., Zapatka, M., Ruppert, A.S., Xue, L., Li, D.H.H., Steggerda, S.M., Versele, M., et al. (2014) Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib. New England Journal of Medicine, 370, 2286-2294. [Google Scholar] [CrossRef]
|
|
[31]
|
Furman, R.R., Cheng, S., Lu, P., Setty, M., Perez, A.R., Guo, A., Racchumi, J., Xu, G., Wu, H., Ma, J., et al. (2014) Ibrutinib Resistance in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 370, 2352-2354. [Google Scholar] [CrossRef]
|
|
[32]
|
Feng, Y.F., Duan, W.M., Cu, X.C. and Xin, M.H. (2019) Bruton’s Tyrosine Kinase (BTK) Inhibitors in Treating Cancer: A Patent Review. Expert Opinion on Therapeutic Patents, 29, 217-241. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Norman, P. (2016) Investigational Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. Expert Opinion on Investigational Drugs, 25, 891-899. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Tinworth, C.P., Lithgow, H., Dittus, L., Bassi, Z.I., Hughes, S.E., Muelbaier, M., Dai, H., Smith, I.E.D., Kerr, W.J., Burley, G.A., et al. (2019) PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding. ACS Chemical Biology, 14, 342-347. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Wen, T.Y., Wang, J.S., Shi, Y.K., Qian, H.L. and Liu, P. (2021) Inhibitors Targeting Bruton’s Tyrosine Kinase in Cancers: Drug Development Advances. Leukemia, 35, 312-332. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Mahajan, S, Ghosh, S., Sudbeck, E.A., Zheng, Y., Downs, S., Hupke, M., et al. (199) Rational Design and Synthesis of a Novel Anti-Leukemic Agent Targeting Bruton’s Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-β-Methyl- N-(2,5-Dibromophenyl)Propenamide]. Journal of Biological Chemistry, 274, 9587-9599. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Honigberg, L.A., Smith, A.M., Sirisawad, M., Verner, E., Loury, D., Chang, B., et al. (2010) The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and Is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107, 13075-13080. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Sibaud, V., Beylot-Barry, M., Protin, C., Vigarios, E., Recher, C. and Ysebaert, L. (2020) Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors. American Journal of Clinical Dermatology, 21, 799-812. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Tillman, B.F., Pauff, J.M., Satyanarayana, G., Talbott, M. and Warner, J.L. (2018) Systematic Review of Infectious Events with the Bruton Tyrosine Kinase Inhibitor Ibrutinib in the Treatment of Hematologic Malignancies. European Journal of Haematology, 100, 325-334. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Wilson, W.H., Young, R.M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.J., Williams, M.P., Shaffer, A.L., Gerecitano, J., et al. (2015) Targeting B Cell Receptor Signaling with Ibru-tinib in Diffuse Large B Cell Lymphoma. Nature Medicine, 21, 922-926. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Xu, L., Tsakmaklis, N., Yang, G., Chen, J.G., Liu, X., Demos, M., Kofides, A., Patterson, C.J., Meid, K., Gustine, J., et al. (2017) Acquired Mutations Associated with Ibrutinib Resistance in Waldenström Macroglobulinemia. Blood, 129, 2519-2525. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Da Cunha-Bang, C. and Niemann, C.U. (2018) Targeting Bruton’s Tyrosine Kinase across B-Cell Malignancies. Drugs, 78, 1653-1663. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Harrington, B.K., Gardner, H.L., Izumi, R., Hamdy, A., Roth-baum, W., Coombes, K.R., et al. (2016) Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Mod-els of B-Cell Non-Hodgkin Lymphoma. PLOS ONE, 11, e159607. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Syed, Y.Y. (2020) Zanubrutinib: first Approval. Drugs, 80, 91-97. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Guo, Y.h., Liu, Y., Hu, N., Yu, D.S., Zhou, C.Y., Shi, G.Y., et al. (2019) Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. Journal of Medicinal Chemistry, 62, 7923-7940. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Kaptein, A., de Bruin, G., Emmelot-van Hoek, M., van de Kar, B., de Jong, A., Gulrajani, M., et al. (2018) Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. Blood, 132, 1871. [Google Scholar] [CrossRef]
|
|
[47]
|
Alsadhan, A., Cheung, J., Gulrajani, M., Gaglione, E.M., Nierman, P., Hamdy, A., et al. (2020) Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lympho-cytic Leukemia Treated with Acalabrutinib. Clinical Cancer Research, 26, 2800-2809. [Google Scholar] [CrossRef]
|
|
[48]
|
Tam, C.S., Trotman, J., Opat, S., Burger, J.A., Cull, G., Gottlieb, D., et al. (2019) Phase 1 Study of the Selective BTK Inhibitor Zanubrutinib in B-Cell Malignancies and Safety and Efficacy Evaluation in CLL. Blood, 134, 851-859. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Wu, J.J., Zhang, M.Z. and Liu, D.L. (2016) Acalabrutinib (ACP-196): A Selective Second-Generation BTK Inhibitor. Journal of Hematology & Oncology, 9, Article No. 21. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Schaff, L.R. and Grommes, C. (2021) Update on Novel Thera-peutics for Primary CNS Lymphoma. Cancers, 13, Article No. 5372. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Jeelall, Y.S. and Horikawa, K. (2011) Oncogenic MYD88 Mutation Drives Toll Pathway to Lymphoma. Immunology & Cell Biology, 89, 659-660. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Ngo, V.N., Young, R.M., Schmitz, R., et al. (2011) Oncogenically Active MYD88 Mutations in Human Lymphoma. Nature, 470, 115-119. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Hilal, T., Maguire, A., Kosiorek, H.E., Rimsza, L.M. and Rosenthal, A.C. (2019) Clinical Features and Cell of Origin Subtyp-ing Using Gene Expression Profiling in HIV-Negative Patients with Primary Central Nervous System Lymphoma. Leu-kemia & Lymphoma, 60, 3581-3583. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Braggio, E., Van Wier, S., Ojha, J., et al. (2015) Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clinical Cancer Research, 21, 3986-3994. [Google Scholar] [CrossRef]
|
|
[55]
|
Nakamura, T., Tateishi, K., Niwa, T., et al. (2016) Recurrent Mutations of CD79B and MYD88 Are the Hallmark of Primary Central Nervous System Lymphomas. Neuropathology and Applied Neurobiology, 42, 279-290. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Lionakis, M.S., Dunleavy, K., Roschewski, M., et al. (2017) Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell, 31, 833-843. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Grommes, C., Tang, S.S., Wolfe, J., et al. (2019) Phase 1b Trial of an Ibrutinib Based Combination Therapy in Recurrent/Refractory CNS Lymphoma. Blood, 133, 436-445. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Young, R.M., Shaffer 3rd, A.L., Phelan, J.D. and Staudt, L.M. (2015) B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma. Seminars in Hematology, 52, 77-85. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Schmitz, R., Wright, G.W., Huang, D.W., et al. (2018) Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 378, 1396-1407. [Google Scholar] [CrossRef]
|
|
[60]
|
Montesinos-Rongen, M., Schmitz, R., Brunn, A., et al. (2010) Mu-tations of CARD11 but Not TNFAIP3 May Activate the NF-kappaB Pathway in Primary CNS Lymphoma. Acta Neu-ropathologica, 120, 529-535. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Soussain, C., Choquet, S., Blonski, M., Leclercq, D., Houillier, C., Rezai, K., Bijou, F., Houot, R., Boyle, E., Gressin, R., et al. (2019) Ibrutinib Monotherapy for Relapse or Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma: Final Analysis of the Phase II ‘Proof-of-Concept’ iLOC Study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network. Euro-pean Journal of Cancer, 117, 121-130. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Rubenstein, J.L., Geng, H., Fraser, E.J., Formaker, P., Chen, L., Sharma, J., Killea, P., Choi, K., Ventura, J., Kurhanewicz, J., et al. (2018) Phase 1 Investigation of Lenalido-mide/Rituximab plus Outcomes of Lenalidomide Maintenance in Relapsed CNS Lymphoma. Blood Advances, 2, 1595-1607. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Tun, H.W., Johnston, P.B., DeAngelis, L.M., Atherton, P.J., Pederson, L.D., Koenig, P.A., Reeder, C.B., Omuro, A.M.P., Schiff, D., O’Neill, B., et al. (2018) Phase 1 Study of Pomalidomide and Dexamethasone for Relapsed/Refractory Primary CNS or Vitreoretinal Lymphoma. Blood, 132, 2240-2248. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Ghesquieres, H., Chevrier, M., Laadhari, M., Chinot, O., Choquet, S., Moluçon-Chabrot, C., Beauchesne, P., Gressin, R., Morschhauser, F., Schmitt, A., et al. (2019) Lenalidomide in Combination with Intravenous Rituximab (REVRI) in Relapsed/Refractory Primary CNS Lymphoma or Primary Intraocular Lymphoma: A Multicenter Prospective ‘Proof of Concept’ Phase II Study of the French Ocu-lo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Annals of Oncology, 30, 621-628. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Wu, C., de Miranda, N., Chen, L., Wasik, A.M., Mansouri, L., Jurczak, W., Galazka, K., Dlugosz-Danecka, M., Machaczka, M., Zhang, H., et al. (2016) Genetic Heterogeneity in Primary and Relapsed Mantle Cell Lymphomas: Impact of Recurrent CARD11 Mutations. Oncotarget, 7, 38180-38190. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Narita, Y., Nagane, M., Mishima, K., Terui, Y., Arakawa, Y., Yonezawa, H., Asai, K., Fukuhara, N., Sugiyama, K., Shinojima, N., et al. (2020) Phase I/II Study of Tirabrutinib, a Second-Generation Bruton’s Tyrosine Kinase Inhibitor, in Relapsed/Refractory Primary Central Nervous System Lym-phoma. Neuro-Oncology, 23, 122-133. [Google Scholar] [CrossRef] [PubMed]
|